High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study

American Journal on Addictions

Volumn 23, Issue 3, 2014, Pages 257-264

  Nosyk, Bohdan ^a,b   Fischer, Benedikt ^b,c,d   Sun, Huiying ^e   Marsh, David C ^f   Kerr, Thomas ^a,g   Rehm, Juergen T ^d   Anis, Aslam H ^e,g  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c Centre for Applied Research in Mental Health Addiction (CARMHA)   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^f NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METHADONE TREATMENT; MULTIVARIATE ANALYSIS; OPIATE ADDICTION; PATIENT COMPLIANCE; PHYSICIAN; POPULATION; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT DURATION; CLINICAL PRACTICE; DRUG UTILIZATION; FACTUAL DATABASE; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; TRENDS; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; BRITISH COLUMBIA; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PHYSICIAN'S PRACTICE PATTERNS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898887901     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2014.12091.x     Document Type: Article

References (61)

1. Popova S, Patra J, Mohapatra S, et al. How many people in Canada use prescription opioids non-medically in general and street drug using populations ? Can J Public Health. 2009; 100: 104-108.
2. Volkow ND, McLellan TA., Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA. 2011; 305: 1346-1347.
3. Fischer B, Nakamura N, Ialomiteanu A, et al. Assessing the prevalence of nonmedical prescription opioid use in the general Canadian population: Methodological issues and questions. Can J Psychiatry. 2010; 55: 606-609.
4. th, 2013].
5. Gunderson EW, Fiellin DA., Office-based maintenance treatment of opioid dependence: How does it compare with traditional approaches ? CNS Drugs. 2008; 22: 99-111.
6. Highlights for 2007 Treatment Episode Data Set (TEDS). 2007. http://oas.samhsa.gov/TEDS2k7highlights/TEDSHighl2k7Tbl1a.htm (accessed: May 23, 2011).
7. Fischer B, Jones W, Krahn M, et al. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf. 20: 1269-1277. doi: 10.1002/pds.2190
8. Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend. 2009; 105: 9-15.
9. Jamison RN, Kauffman J, Katz NP., Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage. 2000; 19: 53-62.
10. Peles E, Schreiber S, Gordon J, et al. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005; 113: 340-346.
11. Portenoy RK, Dole V, Joseph H, et al. Pain management and chemical dependency. Evolving perspectives. JAMA. 1997; 278: 592-593.
12. Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003; 289: 2370-2378.
13. Health Canada. Best practices, methadone maintenance treatment. Prepared by Jamieson, Beals, Lalonde and Associates, Inc. for the Office of Canada's Drug Strategy, Health Canada, 2002.
14. Lugo RA, Satterfield KL, Kern SE., Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005; 19: 13-24.
15. Huxtable CA, Roberts LJ, Somogyi AA, et al. Acute pain management in opioid-tolerant patients: A growing challenge. Anaesth Intensive Care. 2011; 39: 804-823.
16. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer. 2001; 84: 587-593.
17. Davis MP, Walsh D., Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001; 9: 73-83.
18. Martin JE, Inglis J., Pain tolerance and addiction. Br J Soc Clin Psychol. 1965; 4: 224-229.
19. Compton MA., Cold-pressor pain tolerance in opiate and cocaine abusers: Correlates of drug type and use status. Pain Symptom Manage. 1994; 9: 462-473.
20. Compton P, Charuvastra VC, Ling W., Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend. 2001; 63: 139-146.
21. Doverty M, White JM, Somogyi AA, et al. Hyperalgesic responses in methadone maintenance patients. Pain. 2001; 90: 91-96.
22. Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2003; 93: 155-163.
23. Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14: 145-161.
24. Nosyk B, Marshall BDL, Fischer B, et al. Increases in the availability of prescribed opioids in a Canadian setting. Drug Alcohol Depend. 126: 7-12.
25. Fischer B, Bibby M, Bouchard M., Non-medical use and diversion of psychotropic prescription drugs in North America: A review of sourcing routes and control measures. Addiction. 2010; 105: 2062-2070.
26. Kurdyak P, Gomes T, Yao Z, et al. Use of other opioids during methadone therapy: A population-based study. Addiction. 2012; 107: 776-780.
27. College of Pharmacists of British Columbia: Controlled Prescription Program. August 2011. http://library.bcpharmacists.org/D-Legislation-Standards/ D-4-Drug-Distribution/5015-ControlledPrescriptionProgram.pdf (accessed: April 14, 2013).
28. College of Physicians and Surgeons of BC. Medical Practitioner Access to PharmaNet. https://www.cpsbc.ca/node/108 (accessed: April 14, 2013).
29. College of Physicians and Surgeons of BC. Prescription Review Program. https://www.cpsbc.ca/about-college/prescription-review-program (accessed: April 14, 2013).
30. BC Ministry of Health. PharmaNet database: http://www.health.gov.bc.ca/ pharmacare/pharmanet/netindex.html (accessed: January 27, 2012).
31. Population Data BC. www.popdatabc.ca (accessed: February 14, 2011).
32. Cepeda MS, Fife D, Chow W, et al. Assessing opioid shopping behaviour: A large cohort study from a medication dispensing database in the US. Drug Saf. 2012; 35: 325-334.
33. Cepeda MS, Fife D, Chow W, et al. Opioid shopping behavior: How often, how soon, which drugs, and what payment method. J Clin Pharmacol. 2013; 53: 112-117.
34. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008; 300: 2613-2620.
35. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. 2007. http://www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.pdf
36. Schneeweiss S, Seeger SD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2003; 154: 854-864.
37. Nosyk B, MacNab YC, Sun H, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009; 170: 783-792.
38. Raudenbush SW, Bryk AS., Hierarchical Linear Models: Applications and Data Analysis Methods, 2nd edn. Newbury Park, CA: Sage; 2002.
39. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011; 12: S26-S35.
40. Simonsen KW, Normann PT, Ceder G, et al. Fatal poisoning in drug addicts in the Nordic countries in 2007. Forensic Sci Int. 2011; 207: 170-176.
41. Strang J, Hall W, Hickman M, et al. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): Analyses using OD4 index in England and Scotland. BMJ. 2010; 341: c4851.
42. Romelsjö A, Engdahl B, Stenbacka M, et al. Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity ? Addiction. 2010; 105: 1625-1632.
43. Heinemann A, Iwersen-Bergmann S, Stein S, et al. Methadone-related fatalities in Hamburg 1990-1999: Implications for quality standards in maintenance treatment ? Forensic Sci Int. 2000; 113: 449-455.
44. Dhalla IA, Mamdani MM, Sivilotti ML, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009; 181: 891-896.
45. College of Physicians and Surgeons of Ontario. http://www.cpso.on.ca/ uploadedFiles/policies/positions/Opioid%20report%20final.pdf (accessed: February 14, 2012).
46. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171: 686-691.
47. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010; 152: 85-92.
48. Fischer B, Rehm J., Deaths related to the use of prescription opioids. CMAJ. 2009; 181: 881-882.
49. Trafton JA, Oliva EM, Horst DA, et al. Treatment needs associated with pain in substance use disorder patients: Implications for concurrent treatment. Drug Alcohol Depend. 2004; 73: 23-31.
50. Karasz A, Zallman L, Berg K, et al. The experience of chronic severe pain in patients undergoing methadone maintenance treatment. J Pain Symptom Manage. 2004; 28: 517-525.
51. Sharif B, Nosyk B, Sun H, et al. Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in british columbia during its expansion period from 1998-2006. Subst Use Misuse. 2013; 48: 671-682.
52. Fischer B, Rehm J, Patra J, et al. Changes in illicit opioid use across Canada. CMAJ. 2006; 175: 1385.
53. Wilsey BL, Fishman SM, Gilson AM, et al. An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiol Drug Saf. 2011; 20: 1262-1268.
54. McLellan AT, Turner BJ., Chronic noncancer pain management and opioid overdose: Time to change prescribing practices. Ann Intern Med. 2010; 152: 123-124.
55. Martyres RF, Clode D, Burns JM., Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Med J Aust. 2004; 180: 211-214.
56. Paulozzi LJ, Logan JE, Hall AJ, et al. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009; 104: 1541-1548.
57. Brushwood DB., Maximizing the value of electronic prescription monitoring programs. J Law Med Ethics. 2003; 31: 41-54.
58. Gilson AM, Kreis PG., The burden of the nonmedical use of prescription opioid analgesics. Pain Med. 2009; 10: S89-S100.
59. American Society of Addiction Medicine. Measures to counteract prescription drug diversion, misuse and addiction. http://www.asam.org/advocacy/ find-a-policy-statement/view-policy-statement/public-policy-statements/2012/01/ 26/measures-to-counteract-prescription-drug-diversion-misuse-and-addiction
60. Wilsey B, Prasad H., Real-time access to prescription drug monitoring databases. CMAJ. 2012; 184: 1767-1768.
61. Grimes DA, Schulz KF., Bias and causal associations in observational research. Lancet. 2002; 359: 248-252.